It's becoming increasingly clear that women's health is often approached through a male-centric lens, and a recent discussion highlights just how significantly this impacts those with ADHD. According to Therapy in a Nutshell, the medical community has profoundly neglected the critical influence of hormones, particularly estrogen, on women's ADHD symptoms, despite clear biological links [1].
The core issue lies in estrogen's direct role in modulating dopamine, a neurotransmitter essential for executive functions like focus, emotional regulation, and impulse control—all areas where individuals with ADHD experience dysregulation. For women with ADHD, fluctuations in estrogen, which occur daily, throughout the menstrual cycle, during puberty, and across perimenopause and menopause, have a "magnified effect" on their symptoms [1]. When estrogen levels are low or variable, dopamine signals become less efficient, leading to worsened attention, memory, impulsivity, and emotional control, often manifesting as severe "brain fog."
This hormonal interplay explains why many women experience shifts in their ADHD symptoms throughout the month, or a noticeable worsening in their 30s and 40s. Research indicates women with ADHD are almost twice as likely to experience severe PMS (or PMDD), three times as likely to face postpartum depression, and report significantly worse perimenopausal symptoms [1]. This historical oversight stems from medical research and training being predominantly "built around male bodies," leading to the underdiagnosis and undertreatment of ADHD in girls and women, whose differing symptoms were often dismissed as "just anxiety" [1]. This can also affect medication efficacy, with some limited studies suggesting stimulant medication might work differently depending on a woman's cycle [1].